ESTA / Establishment Labs Holdings Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

Separation Agreement by and between Establishment Labs Holdings Inc. and Juan José Chacón-Quirós, dated August 3, 2025

-1- EXHIBIT 10.1 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (“Agreement”) is entered into between Juan José Chacón Quirós (“Employee”) and Establishment Labs Holdings Inc. (“ELHI” or “Company”). WHEREAS, Employee and ELHI entered into an Employment Agreement effective July 1, 2016; and, WHEREAS, Employee informed ELHI on January 10, 2025, that Employee decided to retire

Separation Agreement by and between Establishment Labs S.A. and Juan José Chacón-Quirós, dated August 4, 2025

-1- EXHIBIT 10.2 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (“Agreement”) is entered into between Juan José Chacón Quirós (“Employee”) and Establishment Labs S.A. (“ELSA” or “Company”). WHEREAS, Employee and ELSA entered into an Employment Agreement effective December 26, 2018 (“Employment Agreement”); and, WHEREAS, Employee informed ELSA on January 10, 2025, that Emplo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2025 Date of Report (date of earliest event reported) Establishment Labs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2025 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incor

Establishment Labs Reports Second Quarter 2025 Financial Results

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports Second Quarter 2025 Financial Results NEW YORK, NY, August 7, 2025 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today ann

Consulting Agreement by and between Establishment Labs Holdings Inc. and Juan José Chacón-Quirós, dated August 3, 2025

-1- EXHIBIT 10.3 [***] Certain identified confidential information contained in this document, marked by brackets, has been excluded from this exhibit because it is both (i) not material and (ii) is of the type that the Registrant treats as private or confidential. CONSULTING SERVICES AGREEMENT This Consulting Services Agreement (“Agreement”) is effective as of June 1, 2025 (“Effective Date”), by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establish

Investor Day Welcome Agenda Topic Presenter/Moderator Welcome; Logistics; Agenda Raj Denhoy Corporate Overview Peter Caldini Motiva® USA Business Updates Jeff Ehrhardt US Breast Aesthetic - Panel Ben Newcott Breast Reconstruction Opportunity in the U

Investor Day Welcome Agenda Topic Presenter/Moderator Welcome; Logistics; Agenda Raj Denhoy Corporate Overview Peter Caldini Motiva® USA Business Updates Jeff Ehrhardt US Breast Aesthetic - Panel Ben Newcott Breast Reconstruction Opportunity in the USA Jeff Ehrhardt US Breast Reconstruction - Panel Ben Newcott Innovation Pipeline Roberto de Mezerville GLP-1s and Plastic Surgery Juan José Chacón-Quirós Unlocking New Markets - Panel Juan José Chacón-Quirós Management Q&A AgendaInvestors’ Day Forward Looking Statements and Other Legal Matters This presentation contains forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 12, 2025 Date of Report (date of earliest event reported) Establishment Labs H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 12, 2025 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 23, 2025 Date of Report (date of earliest event reported) Establishment Labs Ho

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 23, 2025 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incorpo

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 20, 2025 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incorpo

May 21, 2025

EXHIBIT 99.1 May 21, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Establishment Labs Holdings, Inc. under Item 4.01 of its Form 8-K dated May 20, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Establishment Labs Holdi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ¨ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establis

Establishment Labs Appoints Peter Caldini as Chief Executive Officer

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Appoints Peter Caldini as Chief Executive Officer NEW YORK, NY, May 7, 2025 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction announced

Establishment Labs Reports First Quarter 2025 Financial Results

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports First Quarter 2025 Financial Results NEW YORK, NY, May 7, 2025 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2025 Date of Report (date of earliest event reported) Establishment Labs Hol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 6, 2025 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ¨ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2025 Date of Report (date of earliest event reported) Establishment Labs Hol

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2025 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incorpor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) x Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ¨ Definitive Proxy State

Establishment Labs Provides Preliminary First Quarter Results and Announces an Investor Day on June 12

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Provides Preliminary First Quarter Results and Announces an Investor Day on June 12 NEW YORK, NY, April 10, 2025 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast ae

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 10, 2025 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incor

List of Subsidiaries of the Registrant.

EXHIBIT 21.1 SUBSIDIARIES OF ESTABLISHMENT LABS HOLDINGS INC. Name of Subsidiary Jurisdiction of Organization Establishment Labs, S.A. Costa Rica Motiva USA, LLC Delaware JAMM Technologies, Inc. Delaware Establishment Labs Produtos par Saude Ltda ** Brazil European Distribution Center Motiva BV * Belgium Motiva Implants France SAS France JEN-Vault AG Switzerland Motiva Nordica AB ** Sweden Motiva

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establishment Labs Holdin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands No

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Building B23

nsider Trading Policy

Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1 Exhibit 19.1

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Table ……… Form S-8 ………………………………………………..………… Establishment Lab Holdings Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value 457(c); 457(h) 750,000(2) $

Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports Fourth Quarter and Full Year 2024 Financial Results and Reaffirms 2025 Guidance NEW YORK, NY, February 26, 2025 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in br

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 26, 2025 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of in

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 15, 2025 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of inc

Establishment Labs Announces CEO Transition ▪Peter Caldini to become Interim CEO effective March 1, 2025 ▪Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Announces CEO Transition ▪Peter Caldini to become Interim CEO effective March 1, 2025 ▪Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance NEW YORK, NY, January 13, 2025 - Establishment Labs Holdings Inc. (NASDAQ: ESTA),

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 10, 2025 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of inc

ESTA / Establishment Labs Holdings Inc. / Qatar Investment Authority - SCHEDULE 13G Passive Investment

SC 13G 1 ss4106433sc13g.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ESTABLISHMENT LABS HOLDINGS INC. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) G31249108 (CUSIP Number) November 7, 2024 (Date of Event Which Requires Filing this Statement) Check the appropriate box to designate the

Item 7 Information

EX-99.A 2 ss4106433ex99a.htm ITEM 7 INFORMATION CUSIP NO. G31249108 SC 13G Page 7 of 8 EXHIBIT A The Schedule 13G to which this attachment is appended is filed by Qatar Investment Authority on behalf of itself and the following subsidiaries: Al-Rayyan Holding LLC

Certificate of Incumbency

EX-99.B 3 ss4106433ex99b.htm CERTIFICATE OF INCUMBENCY CUSIP NO. G31249108 SC 13G Page 8 of 8 EXHIBIT B Certificate of Incumbency **I, Ahmad Mohammed F Q Al-Khanji, Chief of Legal and General Counsel, of Qatar Investment Authority, established by Emiri Decision No 22 in 2005, with its registered office at, Ooredoo Tower (Building 14), Al Dafna Street (Street 801), Al Dafna (Zone 61), Doha, State o

Third Amendment to Credit Agreement, dated as of November 7, 2024, by and among Establishment Labs Holdings Inc., its subsidiaries party thereto as guarantors, the lenders from time to time party thereto, and Oaktree Fund Administration, LLC, as administrative agent for the lenders.

EXHIBIT 10.1 EXECUTION VERSION THIRD AMENDMENT TO CREDIT AGREEMENT AND GUARANTY This Third Amendment to the Credit Agreement and Guaranty (this “Amendment”) is made as of November 7, 2024, by and among ESTABLISHMENT LABS HOLDINGS INC., a BVI business company limited by shares incorporated under the BVI Business Companies Act, 2004 (as amended) with company number 1794254 and with its registered of

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of inc

ESTA / Establishment Labs Holdings Inc. / Capital Research Global Investors - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Establishment Labs Holdings Inc. (Name of Issuer) Common Stock (Title of Class of Securities) G31249108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri

Form of Pre-Funded Warrant to Purchase Common Shares (November 2024)

EXHIBIT 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES ESTABLISHMENT LABS HOLDINGS INC. Warrant Shares: Issue Date:, 20 Initial Exercise Date: , 20 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set fort

Securities Purchase Agreement, dated November 7, 2024, by and among Establishment Labs Holdings Inc. and purchasers named therein.

Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 7, 2024 by and among Establishment Labs Holdings Inc., a company organized under the laws of the British Virgin Islands (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS The

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Esta

Table 1: Newly Registered and Carry Forward Securities

Calculation of Filing Fee Tables S-3 ESTABLISHMENT LABS HOLDINGS INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Ef

765,696 Common Shares Pre-funded Warrants to Purchase 328,154 Common Shares

TABLE OF CONTENTS  Filed pursuant to Rule 424(b)(5)  Registration No. 333-271418   PROSPECTUS SUPPLEMENT (To Prospectus dated April 24, 2023) 765,696 Common Shares Pre-funded Warrants to Purchase 328,154 Common Shares We are offering 765,696 of our common shares, no par value per share (“common shares”), and pre-funded warrants to purchase up to 328,154 common shares (“pre-funded warrants”) in a r

Establishment Labs Announces $50 million Registered Direct Offering

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Announces $50 million Registered Direct Offering NEW YORK, NY, November 7, 2024 - Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reco

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of inc

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of inc

Establishment Labs Reports Third Quarter 2024 Financial Results

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports Third Quarter 2024 Financial Results NEW YORK, NY, November 7, 2024 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today an

Establishment Labs Receives U.S. FDA Approval for Motiva Implants

PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 rdenhoy@establishmentlabs.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 26, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of i

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 20, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of inco

Employment Agreement between the Registrant and Fillipo "Peter" Caldini dated effective as of August 20, 2024

ESTABLISHMENT LABS HOLDINGS INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this Agreement is made and entered into as of August 15, 2024 Effective Date ESTABLISHMENT LABS HOLDINGS INC., a British Virgin Islands company (the Company and Filip Caldini, an individual Executive Background WHEREAS, the Company desires to employ the Executive for the term hereof; WHEREAS, the Executive desires to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establish

Establishment Labs Reports Second Quarter 2024 Financial Results

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports Second Quarter 2024 Financial Results NEW YORK, NY, August 6, 2024 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today ann

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 6, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incor

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 16, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2024 Date of Report (date of earliest event reported) Establishment Labs Ho

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incorpo

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 24, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incorpo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establis

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incorpor

Establishment Labs Reports First Quarter 2024 Financial Results

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports First Quarter 2024 Financial Results NEW YORK, NY, May 8, 2024 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) x Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ¨ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 2, 2024 Date of Report (date of earliest event reported) Establishment Labs H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 2, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of incorp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands No

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Building B15

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Table ……… Form S-8 ………………………………………………..………… Establishment Lab Holdings Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value 457(c); 457(h) 750,000(2) $

First Amendment to Credit Agreement, dated as of January 12, 2023, by and among Establishment Labs Holdings Inc., its subsidiaries party thereto as guarantors, the lenders from time to time party thereto, and Oaktree Fund Administration, LLC, as administrative agent for the lenders.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establishment Labs Holdin

Policy Regarding the Recoupment of Certain Compensation Payments

EXHIBIT 97.1 ESTABLISHMENT LABS HOLDINGS INC. Policy Regarding the Recoupment of Certain Compensation Payments As Adopted by the Board of Directors Effective as of August 9, 2023 In the event Establishment Labs Holdings Inc. (the “Company”) is required to prepare an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities

List of Subsidiaries of the Registrant.

EXHIBIT 21.1 SUBSIDIARIES OF ESTABLISHMENT LABS HOLDINGS INC. Name of Subsidiary Jurisdiction of Organization Establishment Labs, S.A. Costa Rica Motiva USA, LLC Delaware JAMM Technologies, Inc. Delaware Establishment Labs Produtos par Saude Ltda Brazil European Distribution Center Motiva BV * Belgium Motiva Implants France SAS France JEN-Vault AG Switzerland Motiva Nordica AB ** Sweden Motiva Imp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-38593 CUSIP Number: G31249108 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2024 Date of Report (date of earliest event reported) Establishment La

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 28, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of in

Establishment Labs Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Guidance NEW YORK, NY, February 28, 2024 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in bre

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of in

Second Amendment to Credit Agreement, dated as of February 21, 2024, by and among Establishment Labs Holdings Inc., its subsidiaries party thereto as guarantors, the lenders from time to time party thereto, and Oaktree Fund Administration, LLC, as administrative agent for the lenders.

EXECUTION VERSION CONFIDENTIAL SECOND AMENDMENT TO CREDIT AGREEMENT AND GUARANTY This Second Amendment to the Credit Agreement and Guaranty (this “Amendment”) is made as of February 21, 2024, by and among ESTABLISHMENT LABS HOLDINGS INC.

ESTA / Establishment Labs Holdings Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm243309d21sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Establishment Labs Holdings Inc. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Chec

ESTA / Establishment Labs Holdings Inc. / RTW INVESTMENTS, LP - ESTABLISHMENT LABS HOLDINGS INC. Passive Investment

SC 13G/A 1 p24-0386sc13ga.htm ESTABLISHMENT LABS HOLDINGS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Establishment Labs Holdings Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statem

ESTA / Establishment Labs Holdings Inc. / BROWN ADVISORY INC - BROWN ADVISORY INC Passive Investment

SC 13G/A 1 estaa320924.htm BROWN ADVISORY INC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Establishment Labs Holdings Inc. (Name of Issuer) (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to

ESTA / Establishment Labs Holdings Inc. / Chacon Quiros Juan Jose - SC 13G Passive Investment

SC 13G 1 form13gchaconquiros123123.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Establishment Labs Holdings Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) G31249 108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement)

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 31, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of inc

2,000,000 Shares Common Shares Offered by the Selling Shareholders

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(7)  Registration No. 333-271418 PROSPECTUS SUPPLEMENT (To Prospectus dated April 24, 2023) 2,000,000 Shares Common Shares Offered by the Selling Shareholders This prospectus supplement relates to the resale from time to time of up to 2,000,000 common shares of Establishment Labs Holdings Inc. by the selling shareholders listed on page S-9, including

Calculation of Filing Fee Tables (Form Type) Establishment Labs Holdings Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Establishment Labs Holdings Inc.

ESTABLISHMENT LABS ANNOUNCES $50 MILLION PRIVATE PLACEMENT AND PRELIMINARY UNAUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2023

EXHIBIT 99.1 ESTABLISHMENT LABS ANNOUNCES $50 MILLION PRIVATE PLACEMENT AND PRELIMINARY UNAUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2023 JANUARY 9, 2024 NEW YORK-(BUSINESS WIRE)- Establishment Labs Holdings Inc. (NASDAQ: ESTA) (“Establishment Labs” or the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast

Securities Purchase Agreement, dated January 9, 2024

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2024 by and among Establishment Labs Holdings Inc., a company organized under the laws of the British Virgin Islands (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A.The

Form of Pre-Funded Warrant to Purchase Common Shares

EXHIBIT 4.1 THIS SECURITY AND THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATI

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 9, 2024 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 98-1436377 (State or other jurisdiction of inco

Registration Rights Agreement, dated January 9, 2024

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2024 by and among Establishment Labs Holdings Inc., a company organized under the laws of the British Virgin Islands (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 8, 2023 Date of Report (date of earliest event reported) Establishment Lab

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 8, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Esta

Establishment Labs Reports Third Quarter 2023 Financial Results

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports Third Quarter 2023 Financial Results NEW YORK, NY, November 7, 2023 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today an

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establish

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2023 Date of Report (date of earliest event reported) Establishment Labs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of i

Establishment Labs Reports Record Second Quarter 2023 Financial Results

Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 24, 2023 Date of Report (date of earliest event reported) Establishment Labs Ho

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 24, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inc

Memorandum and Articles of Association of the Registrant

exhibit31 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION AND ARTICLES OF ASSOCIATION OF ESTABLISHMENT LABS HOLDINGS INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establis

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 8, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inco

Establishment Labs Reports Record First Quarter 2023 Financial Results

Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.

Inc. and Jefferies LLC, J.P. Morgan Securities, LLC, Citigroup Global Markets Inc. and Cowen

Exhibit 1.1 Execution Version Establishment Labs Holdings Inc. 1,100,000 Common Shares Underwriting Agreement April 24, 2023 Jefferies LLC J.P. Morgan Securities LLC Citigroup Global Markets Inc. COWEN AND COMPANY, LLC As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 101

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 24, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of (

1,100,000 Shares Common Shares

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-271418 Prospectus Supplement (To Prospectus dated April 24, 2023) 1,100,000 Shares Common Shares Establishment Labs Holdings Inc. is offering 1,100,000 common shares. Our common shares are listed on The Nasdaq Capital Market under the symbol “ESTA.” The closing price of our common shares on The Nasdaq Capital Market on April

Calculation of Filing Fee Tables Form S-3 (Form Type) Establishment Labs Holdings Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Establishment Labs Holdings Inc.

Form of Indenture for Subordinated Debt Securities.

Exhibit 4.2 ESTABLISHMENT LABS HOLDINGS INC.                                       INDENTURE Dated as of , 20 [                                       ] Trustee Subordinated Securities TABLE OF CONTENTS    Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 24, 2023 Date of Report (date of earliest event reported) Establishment Labs

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 24, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of (

Form of Indenture for Senior Debt Securities.

Exhibit 4.1 ESTABLISHMENT LABS HOLDINGS INC. INDENTURE Dated as of , 20 [ ] Trustee Senior Debt Securities TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable i

    Shares Common Shares

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Calculation of Filing Fees Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Establishment Labs Holdings Inc.

Establishment Labs Announces Preliminary Unaudited Results for First Quarter 2023

EX-99.1 2 tm2313518d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Establishment Labs Announces Preliminary Unaudited Results for First Quarter 2023 NEW YORK, N.Y., April 24, 2023 - Establishment Labs Holdings Inc. (NASDAQ: ESTA) (the “Company”), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced preli

As filed with the Securities and Exchange Commission on April 24, 2023.

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 24, 2023.

Establishment Labs Notes Presentation of 3-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2023

Exhibit 99.1 Establishment Labs Notes Presentation of 3-Year Results from Motiva U.S. IDE Study at The Aesthetic Meeting 2023 New York, NY, April 20, 2023 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today noted the presentation of a study update on the

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 20, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) x Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ¨ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ¨ Definitive Proxy State

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Table ……… Form S-8 ………………………………………………..………… Establishment Lab Holdings Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value 457(c); 457(h) 750,000(2) $

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands No

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Building B15

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establishment Labs Holdin

List of Subsidiaries of the Registrant.

EXHIBIT 21.1 SUBSIDIARIES OF ESTABLISHMENT LABS HOLDINGS INC. Name of Subsidiary Jurisdiction of Organization Establishment Labs, S.A. Costa Rica Motiva USA, LLC Delaware JAMM Technologies, Inc. Delaware Establishment Labs Produtos par Saude Ltda Brazil European Distribution Center Motiva BVBA * Belgium Motiva Implants France SAS France JEN-Vault AG Switzerland Motiva Nordica AB ** Sweden Motiva I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 27, 2023 Date of Report (date of earliest event reported) Establishment La

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 27, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction o

Establishment Labs Submits Module Four to U.S. FDA for Premarket Approval of Motiva and Reports Record Fourth Quarter and Full Year 2022 Financial Results

Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.

ESTA / Establishment Labs Holdings Inc / RTW INVESTMENTS, LP - ESTABLISHMENT LABS HOLDINGS INC. Passive Investment

SC 13G/A 1 p23-0491sc13ga.htm ESTABLISHMENT LABS HOLDINGS INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Establishment Labs Holdings Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statem

ESTA / Establishment Labs Holdings Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm236168d33sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Establishment Labs Holdings Inc. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Chec

ESTA / Establishment Labs Holdings Inc / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment

SC 13G/A 1 estaa220923.htm BROWN ADVISORY INCORPORATED UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Establishment Labs Holdings Inc. (Name of Issuer) (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropria

ESTA / Establishment Labs Holdings Inc / Chacon Quiros Juan Jose - SC 13G/A Passive Investment

Founder & CEO Establishment Labs JUAN JOSÉ CHACÓN-QUIRÓS JANUARY 12th, 2023 41 Annual J.P. Morgan Healthcare Conference st FORWARD LOOKING STATEMENTS AND OTHER LEGAL MATTERS This presentation contains forward-looking statements within the meaning of

Founder & CEO Establishment Labs JUAN JOSÉ CHACÓN-QUIRÓS JANUARY 12th, 2023 41 Annual J.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 11, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 9, 2023 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Establishment Labs Announces Preliminary Unaudited Revenue for Fourth Quarter and Fiscal Year 2022

Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 1, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Employment Agreement by and between Registrant and Paul D. Rodio, dated December 1, 2022

EXHIBIT 10.1 ESTABLISHMENT LABS HOLDINGS INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of December 1, 2022 (the ?Effective Date?), by and between ESTABLISHMENT LABS HOLDINGS INC., a British Virgin Islands company (the ?Company?) and PAUL D. RODIO, an individual (the ?Executive?). Background WHEREAS, the Company desires to employ the Executive fo

Separation and General Release Agreement by and between Registrant and Pratip Dastidar, dated September 2, 2022

EXHIBIT 10.1 SEPARATION AND GENERAL RELEASE AGREEMENT This Separation and General Release Agreement (this ?Agreement?) is entered into this second day of September 2022, by and between Establishment Labs Holdings Inc., a British Virgin Islands company (the ?Company?) and Pratip Dastidar, an individual (the ?Executive?). WHEREAS, Executive was employed by the Company pursuant to the terms of an emp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Estab

Employment Agreement by and between Registrant and Samuel Ross Mansbach, dated August 22, 2022

EXHIBIT 10.2 ESTABLISHMENT LABS HOLDINGS INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of August 22, 2022 (the ?Effective Date?), by and between ESTABLISHMENT LABS HOLDINGS INC., a British Virgin Islands company (the ?Company?) and SAMUEL ROSS MANSBACH, an individual (the ?Executive?). Background WHEREAS, the Company desires to employ the Execut

Establishment Labs Reports Third Quarter 2022 Financial Results

Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2022 Date of Report (date of earliest event reported) Establishment Lab

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 2, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction o

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 18, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Form of Share Option Agreement (US) under the 2018 Equity Incentive Plan

EXHIBIT 10.6 ESTABLISHMENT LABS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN SHARE OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Establishment Labs Holdings Inc. 2018 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Share Option Agreement, which includes the Notice of Share Option Grant (the ?Notice of Grant?), the Terms and Conditions of Shar

Form of Restricted Share Unit Award Agreement (International) under the 2018 Equity Incentive Plan

EXHIBIT 10.9 ESTABLISHMENT LABS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN RESTRICTED SHARE UNIT AWARD AGREEMENT THIS RESTRICTED SHARE UNIT AWARD AGREEMENT (this ?Agreement?) is by and between Establishment Labs Holdings Inc., a British Virgin Islands company (the ?Company?), and the Participant (the ?Participant?). Pursuant to the Establishment Labs Holdings Inc. 2018 Equity Incentive Plan (the ?Pl

Form of Restricted Share Unit Award Agreement (US) under the 2018 Equity Incentive Plan

EXHIBIT 10.8 ESTABLISHMENT LABS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN RESTRICTED SHARE UNIT AWARD AGREEMENT THIS RESTRICTED SHARE UNIT AWARD AGREEMENT (this ?Agreement?) is by and between Establishment Labs Holdings Inc., a British Virgin Islands company (the ?Company?), and the Participant (the ?Participant?). Pursuant to the Establishment Labs Holdings Inc. 2018 Equity Incentive Plan (the ?Pl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establishm

Form of Share Option Agreement (International) under the 2018 Equity Incentive Plan

EXHIBIT 10.7 ESTABLISHMENT LABS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN SHARE OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Establishment Labs Holdings Inc. 2018 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Share Option Agreement, which includes the Notice of Share Option Grant (the ?Notice of Grant?), the Terms and Conditions of Shar

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 8, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of i

Establishment Labs Reports Record Second Quarter 2022 Financial Results

Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 17, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of in

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 1, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inc

Master Supply Agreement, effective as of May 13, 2022, by and between Establishment Labs S. A. and Nusil Technology LLC.

EXHIBIT 10.1 Certain identified information has been redacted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been redacted. MASTER SUPPLY AGREEMENT THIS MASTER SUPPLY AGREEMENT (the ?Agreement?) is made effective as of the 13th day of May, 2022 (the ?Effective Date?), by and between NuSil

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 26, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inc

Amendment to the Supply Agreement by and between Establishment Labs, S.A. and NuSil Technology LLC, dated

EXHIBIT 10.4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establish

ent to the Supply Agreement by and between Establishment Labs, S.A. and NuSil Technology LLC, dated

EXHIBIT 10.3

Establishment Labs Reports Record First Quarter 2022 Financial Results

Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) x Definitive Proxy State

U.S. Security Agreement, dated as of April 26, 2022, by Establishment Labs Holdings Inc, each other grantor from time to time party thereto, and Oaktree Fund Administration, LLC, as administrative agent for the lenders.

EXHIBIT 10.2 EXECUTION VERSION U.S. SECURITY AGREEMENT by and among ESTABLISHMENT LABS HOLDINGS INC., a BVI business company (the ?Borrower?) the Borrower?s Subsidiaries named in the signature pages hereto or having acceded hereto pursuant to Section 24 (each a ?Subsidiary Guarantor? and, together with the Borrower, each a ?Grantor? and, collectively, the ?Grantors?) and OAKTREE FUND ADMINISTRATIO

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 26, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of i

Credit Agreement and Guaranty, dated as of April 26, 2022, by and among Establishment Labs Holdings Inc., its subsidiaries party thereto as guarantors, the lenders from time to time party thereto, and Oaktree Fund Administration, LLC, as administrative agent for the lenders.

EXHIBIT 10.1 EXECUTION VERSION CREDIT AGREEMENT AND GUARANTY dated as of April 26, 2022 by and among ESTABLISHMENT LABS HOLDINGS INC., as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO, as the Lenders, and OAKTREE FUND ADMINISTRATION, LLC, as the Administrative Agent U.S. $225,000,000 TABLE OF CONTENTS Section 1

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 1, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of in

Form of Restricted Share Unit Award Agreement under the 2018 Equity Incentive Plan

EXHIBIT 10.26 ESTABLISHMENT LABS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN RESTRICTED SHARE UNIT AWARD AGREEMENT THIS RESTRICTED SHARE UNIT AWARD AGREEMENT (this ?Agreement?) is dated as of [, 20] by and between Establishment Labs Holdings Inc., a British Virgin Islands company (the ?Company?), and [] (the ?Participant?). W I T N E S S E T H WHEREAS, pursuant to the Establishment Labs Holdings Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 1, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establishment Labs Holdin

Filing Fee Table.

EXHIBIT 107 Calculation of Filing Fee Table ??? Form S-8 ??????????????????..???? Establishment Lab Holdings Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Shares, no par value 457(c); 457(h) 750,000(2) $

Establishment Labs Reports Fourth Quarter and Full Year 2021 Financial Results; Record Fourth Quarter Revenue of $35.3 Million

Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.

Form of Share Option Agreement (US) under the 2018 Equity Incentive Plan

EXHIBIT 10.24 ESTABLISHMENT LABS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN SHARE OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Establishment Labs Holdings Inc. 2018 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Share Option Agreement, which includes the Notice of Share Option Grant (the ?Notice of Grant?), the Terms and Conditions of Sha

First Amendment to the Supply Agreement by and between Establishment Labs, S.A. and NuSil Technology LLC, dated January 1, 2022.

EXHIBIT 10.23 FIRST AMENDMENT TO THE SUPPLY AGREEMENT DATED AUGUST 18, 2016 This First Amendment (?Amendment?) to the Supply Agreement dated August 18, 2016, is made effective as of the 1st day of January, 2022 (the ?Effective Date?), by and between NuSil Technology LLC, a Delaware limited liability company with its principal office at 1050 Cindy Lane, Carpinteria, California 93013 USA (?NuSil?),

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S‑8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands No

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S?8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Establishment Labs Holdings Inc. (Exact name of Registrant as specified in its charter) British Virgin Islands Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) Building B15

List of Subsidiaries of the Registrant.

EXHIBIT 21.1 SUBSIDIARIES OF ESTABLISHMENT LABS HOLDINGS INC. Name of Subsidiary Jurisdiction of Organization Establishment Labs, S.A. Costa Rica Motiva USA, LLC Delaware JAMM Technologies, Inc. Delaware Establishment Labs Produtos par Saude Ltda Brazil European Distribution Center Motiva BVBA * Belgium Motiva Implants France SAS France JEN-Vault AG Switzerland Motiva Nordica AB ** Sweden Motiva I

Form of Share Option Agreement (International) under the 2018 Equity Incentive Plan

EXHIBIT 10.25 ESTABLISHMENT LABS HOLDINGS INC. 2018 EQUITY INCENTIVE PLAN SHARE OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Establishment Labs Holdings Inc. 2018 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Share Option Agreement, which includes the Notice of Share Option Grant (the ?Notice of Grant?), the Terms and Conditions of Sha

ESTA / Establishment Labs Holdings Inc / RTW INVESTMENTS, LP - ESTABLISHMENT LABS HOLDINGS INC. Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Establishment Labs Holdings Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t

ESTA / Establishment Labs Holdings Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ESTABLISHMENT LABS HOLDINGS INC. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul

ESTA / Establishment Labs Holdings Inc / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Establishment Labs Holdings Inc. (Name of Issuer) (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch

ESTA / Establishment Labs Holdings Inc / Chacon Quiros Juan Jose - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Establishment Labs Holdings Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) G31249 108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

Establishment Labs Announces Preliminary Fourth Quarter and Fiscal Year 2021 Revenue

Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 10, 2022 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Establishment Labs Announces Appointment of Raj Denhoy as Chief Financial Officer

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415-828-1044 [email protected] Establishment Labs Announces Appointment of Raj Denhoy as Chief Financial Officer SANTA BARBARA, Calif., December 13, 2021 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women?s health and wellness, principally in breast aesthetics

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 8, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 8, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.

EXHIBIT 10.1 ESTABLISHMENT LABS HOLDINGS INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is dated as of [DATE] (the ?Effective Date?), and is between Establishment Labs Holdings Inc., a company incorporated under the laws of the British Virgin Islands (the ?Company?), and [NAME] (?Indemnitee?). RECITALS A. Indemnitee?s service to the Company substantially benefits

Establishment Labs Announces Appointment of Leslie Gillin to Board of Directors

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415-828-1044 [email protected] Establishment Labs Announces Appointment of Leslie Gillin to Board of Directors SANTA BARBARA, Calif., December 10, 2021 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women?s health and wellness, principally in breast aesthetics an

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Establishment Labs Reports Third Quarter 2021 Financial Results and Raises Full Year Guidance

EX-99.1 2 esta3q21pressrelease-ex991.htm EX-99.1 Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports Third Quarter 2021 Financial Results and Raises Full Year Guida

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Estab

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establishm

Establishment Labs Reports Record Second Quarter 2021 Financial Results and Raises Full Year Guidance

Coyol Free Zone & Business Park Building, 4th Street, Building B-15, Alajuela, COSTA RICA 1187 Coast Village Road, Suite 1-402, Santa Barbara CA 93108, USA EXHIBIT 99.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of in

Establishment Labs Announces Appointment of Ann Custin and Bryan Slotkin to Board of Directors

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415-828-1044 [email protected] Establishment Labs Announces Appointment of Ann Custin and Bryan Slotkin to Board of Directors SANTA BARBARA, Calif., July 15, 2021 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women?s health, initially in the breast aesthetics and reconstruction ma

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 13, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of in

Establishment Labs Announces Departure of CFO and Appointment of Raj Denhoy as Interim CFO • Company also announces preliminary second quarter 2021 revenue of $31 million to $32 million

EX-99.1 2 ex9918kpr71221.htm EX-99.1 EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415-828-1044 [email protected] Establishment Labs Announces Departure of CFO and Appointment of Raj Denhoy as Interim CFO • Company also announces preliminary second quarter 2021 revenue of $31 million to $32 million SANTA BARBARA, Calif., July 12, 2021 - Establishment Labs Holdings Inc.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 7, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inc

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 24, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inc

Establishment Labs Announces Pratip Dastidar Has Joined the Company as Head of Global Operations

EX-99.1 3 ex9918kpr51821.htm EX-99.1 EXHIBIT 99.1 Establishment Labs Announces Pratip Dastidar Has Joined the Company as Head of Global Operations SANTA BARBARA, Calif., May 18, 2021 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, announced today that Pratip Dastidar has been ap

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 17, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inc

Employment Agreement by and between Registrant and Pratip Dastidar, dated May 17, 2021.

EXHIBIT 10.1 ESTABLISHMENT LABS HOLDINGS INC. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of May 17, 2021 (the ?Effective Date?), by and between ESTABLISHMENT LABS HOLDINGS INC., a BVI corporation (the ?Company?) and Pratip Dastidar, an individual (the ?Executive?). Background WHEREAS, the Company desires to employ the Executive for the term hereof

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establish

Establishment Labs Reports Record First Quarter 2021 Financial Results and Raises Full Year Guidance

EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports Record First Quarter 2021 Financial Results and Raises Full Year Guidance SANTA BARBARA, Calif., May 5, 2021 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women?s health, initially in the breast aesthetics and reconstructio

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 5, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inco

- DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) x Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 19, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of i

List of Subsidiaries of the Registrant.

EXHIBIT 21.1 SUBSIDIARIES OF ESTABLISHMENT LABS HOLDINGS INC. Name of Subsidiary Jurisdiction of Organization Establishment Labs, S.A. Costa Rica Motiva USA, LLC Delaware JAMM Technologies, Inc. Delaware Establishment Labs Produtos par Saude Ltda Brazil European Distribution Center Motiva BVBA * Belgium Motiva Implants France SAS France JEN-Vault AG Switzerland Motiva Nordica AB ** Sweden Motiva I

- S-8

As filed with the Securities and Exchange Commission on March 15, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establishment Labs Holdin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 10, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of i

Establishment Labs Reports Fourth Quarter and Full Year 2020 Financial Results; Record Fourth Quarter Revenue of $27.0 Million

EX-99.1 2 esta4q20pressrelease-ex991.htm EX-99.1 EXHIBIT 99.1 PRESS RELEASE Investor/Media Contact: Raj Denhoy 415 828-1044 [email protected] Establishment Labs Reports Fourth Quarter and Full Year 2020 Financial Results; Record Fourth Quarter Revenue of $27.0 Million SANTA BARBARA, Calif., March 10, 2021 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Establishment Labs Holdings Inc. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securitie

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 15, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction o

Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Shares, No Par Value, of Establishment Labs Holdings Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ESTABLISHMENT LABS HOLDINGS INC. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securiti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ESTABLISHMENT LABS HOLDINGS INC. (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule

JOINT FILING STATEMENT PURSUANT TO RULE 13D-1(K)(1)

EX-1 2 ex1.htm Exhibit 1 JOINT FILING STATEMENT PURSUANT TO RULE 13D-1(K)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. 2 under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, of Establishment Labs Holdings Inc., together with any or all amendments thereto, when and if appropriate. The parties hereto further consent

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Establishment Labs Holdings Inc. (Name of Issuer) Common Shares (Title of Class of Securities) (CUSIP Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Establishment Labs Holdings Inc. (Name of Issuer) (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Establishment Labs Holdings Inc. (Name of Issuer) (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X]

Establishment Labs Hosts Investor Event for its Motiva MIA® System for Minimally Invasive Augmentation •Minimally Invasive creates a new product category in breast aesthetics with a total addressable market of $4-5 billion •Clinical study shows signi

EXHIBIT 99.1 Establishment Labs Hosts Investor Event for its Motiva MIA® System for Minimally Invasive Augmentation •Minimally Invasive creates a new product category in breast aesthetics with a total addressable market of $4-5 billion •Clinical study shows significant benefits compared to traditional breast augmentation surgery, with procedures performed without general anesthesia and women exper

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 9, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Establishment Labs Holdings Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) G31249 108 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 28, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Establishment Labs Reports Preliminary Results for Fourth Quarter and Fiscal Year 2020 •Preliminary Revenue of $26.5 million to $27.5 million for the 4th Quarter, and $84.2 million to $85.2 million for Fiscal Year 2020 •Strong Performance Throughout

EXHIBIT 99.1 Establishment Labs Reports Preliminary Results for Fourth Quarter and Fiscal Year 2020 •Preliminary Revenue of $26.5 million to $27.5 million for the 4th Quarter, and $84.2 million to $85.2 million for Fiscal Year 2020 •Strong Performance Throughout Europe and Rebound to Pre-Pandemic Levels in Latin America Drive Record Quarterly Sales •Cash Balance at December 31, 2020 an Estimated $

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 11, 2021 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 14, 2020 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction o

Motiva Ergonomix2 Platform and Motiva Mia Implant Receive CE Mark •Commercial Launch of Ergonomix2 Planned for 2021 •Approval Accelerates Path to Europe for Motiva Mia •Pre-Commercial European Mia Procedures to Begin in Second Half of 2021

EX-99.1 2 ex9918kcemark.htm EX-99.1 EXHIBIT 99.1 Motiva Ergonomix2 Platform and Motiva Mia Implant Receive CE Mark •Commercial Launch of Ergonomix2 Planned for 2021 •Approval Accelerates Path to Europe for Motiva Mia •Pre-Commercial European Mia Procedures to Begin in Second Half of 2021 SANTA BARBARA, Calif., Dec. 14, 2020 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Estab

Establishment Labs Reports Third Quarter 2020 Financial Results

EX-99.1 2 esta3q20pressrelease-e.htm EX-99.1 EXHIBIT 99.1 Establishment Labs Reports Third Quarter 2020 Financial Results SANTA BARBARA, Calif., November 9, 2020 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the third quarter ended Sep

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 9, 2020 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 21, 2020 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of

Establishment Labs Reports Preliminary Third Quarter Revenue and Cash Balance •$22 million to $23 million 3rd Quarter Preliminary Revenue •Cash Balance at September 30, 2020 an Estimated $81.0 million •Company to Announce Full 3rd Quarter Results on

EXHIBIT 99.1 Establishment Labs Reports Preliminary Third Quarter Revenue and Cash Balance •$22 million to $23 million 3rd Quarter Preliminary Revenue •Cash Balance at September 30, 2020 an Estimated $81.0 million •Company to Announce Full 3rd Quarter Results on November 9 SANTA BARBARA, Calif., October 21, 2020 – Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focuse

ESTA / ESTABLISHMENT LABS HOLDINGS INC. / PURA VIDA INVESTMENTS, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Establishment Labs Holdings Inc.

Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1)

Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Shares, No Par Value, of Establishment Labs Holdings Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 21, 2020 Date of Report (date of earliest event reported) Establishment L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 21, 2020 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction

Annual Report - 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-38593 Establishment Labs Holdings

-

September 25, 2020 VIA EDGAR AND COURIER United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Mail Stop 3030 Washington, D.

Establishment Labs Finalizes Distribution Agreement with Puregraft LLC

EXHIBIT 99.1 Establishment Labs Finalizes Distribution Agreement with Puregraft LLC SANTA BARBARA, Calif., September 25, 2020 – Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it has finalized an amendment to its distribution agreement with Puregraft LLC for Puregr

Second Amendment to Exclusive Distribution Agreement by and between Establishment Labs S.A. and Puregraft LLC dated September 21, 2020.

EXHIBIT 10.1 Certain identified confidential information contained in this document, marked by brackets, has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SECOND AMENDMENT TO EXCLUSIVE DISTRIBUTION AGREEMENT This Second Amendment to the Exclusive Distribution Agreement (this “Second Amendment”) is made and entered

Fourth Amendment to Credit Agreement, by and among Establishment Labs Holdings Inc., the subsidiary guarantors party thereto, the lenders party thereto and Madryn Health Partners LP, as administrative agent

ex101executedmadrynfo344 EXECUTION VERSION FOURTH AMENDMENT TO CREDIT AGREEMENT THIS FOURTH AMENDMENT TO CREDIT AGREEMENT (this “Agreement”) dated as of August 5, 2020 (the “Fourth Amendment Effective Date”) is entered into among ESTABLISHMENT LABS HOLDINGS INC.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establishm

Establishment Labs Reports Second Quarter 2020 Financial Results

EXHIBIT 99.1 Establishment Labs Reports Second Quarter 2020 Financial Results NEW YORK, August 6, 2020 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the second quarter ended June 30, 2020. Second Quarter Highlights and Outlook •Worldwi

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 1, 2020 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of i

Establishment Labs Announces Transition to a Direct Sales Force in Italy

EXHIBIT 99.2 Establishment Labs Announces Transition to a Direct Sales Force in Italy NEW YORK, Thursday, August 6, 2020 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced it has entered into a definitive agreement with its Italian distributor to transition to a dir

Asset Purchase Agreement by and between Motiva Italy S.r.l. and Orion Trading S.r.l. dated as of August 1, 2020

EX-2.1 2 ngorionmotivaitalyasse.htm EX-2.1 EXHIBIT 2.1 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (along with the exhibits and schedules hereto, this “Agreement”) is dated August 1, 2020 (the “Effective Date”), and is entered into by and between MOTIVA ITALY S.r.l., a corporation organized under the laws of Italy, having its registered office at Piazza Filippo Meda 3, 20121 Milano, wit

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 26, 2020 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of in

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 18, 2020 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of in

Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 22, 2020 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inc

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establish

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 7, 2020 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of inco

Establishment Labs Reports Record First Quarter 2020 Financial Results

EXHIBIT 99.1 Establishment Labs Reports Record First Quarter 2020 Financial Results NEW YORK, May 7, 2020 - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the first quarter ended March 31, 2020. First Quarter Highlights and Outlook • Worl

ESTA / ESTABLISHMENT LABS HOLDINGS INC. DEF 14A - - DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) x Definitive Proxy State

List of Subsidiaries of the Registrant.

EXHIBIT 21.1 SUBSIDIARIES OF ESTABLISHMENT LABS HOLDINGS INC. Name of Subsidiary Jurisdiction of Organization Establishment Labs, S.A. Costa Rica Motiva USA, LLC Delaware JAMM Technologies, Inc. Delaware Establishment Labs Produtos par Saude Ltda Brazil European Distribution Center Motiva BVBA * Belgium Motiva Implants France SAS France JEN-Vault AG Switzerland Motiva Nordica AB ** Sweden Motiva I

ESTA / ESTABLISHMENT LABS HOLDINGS INC. 10-K - Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38593 Establishment Labs Holdin

ESTA / ESTABLISHMENT LABS HOLDINGS INC. S-8 - - S-8

As filed with the Securities and Exchange Commission on March 16, 2020 Registration No.

Establishment Labs Reports Fourth Quarter and Full Year 2019 Financial Results

EX-99.1 2 esta4q19pressrelease-ex991.htm EXHIBIT 99.1 EXHIBIT 99.1 Establishment Labs Reports Fourth Quarter and Full Year 2019 Financial Results March 16, 2020 NEW YORK - Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on women’s health, initially in the breast aesthetics and reconstruction market, today announced its financial results for the fourth quarter

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 16, 2020 Date of Report (date of earliest event reported) Establishment Labs Holdings Inc. (Exact name of registrant as specified in its charter) British Virgin Islands 001-38593 Not applicable (State or other jurisdiction of i

Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

EX-4.8 2 exhibit48q42019.htm EXHIBIT 4.8 Exhibit 4.8 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Establishment Labs Holdings Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common shares, no par value per share. As used in this summary, the te